Please ensure Javascript is enabled for purposes of website accessibility

Alnylam Pharmaceuticals, Inc.'s Double-Digit "Earnings" Fall

By Brian Orelli, PhD - May 4, 2016 at 2:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech's numbers are meaningless, but an update on one of its programs sent the stock down.

What: Alnylam Pharmaceuticals (ALNY -2.93%) released earnings on Monday after the bell and fell 11.6% on Tuesday.

Of course, without any products on the market, the biotech's earnings don't really matter. But for the record, Alnylam recorded $7.3 million in revenue, mostly from partners Sanofi and The Medicines Company (MDCO). The net loss for the quarter came in at $103 million, but much of that was non-cash GAAP expenses. Most importantly the company ended the quarter with $1.2 billion in the bank and increased its guidance for year-end cash to "over $1 billion," including $150 million of restricted marketable securities related to a credit agreement being used to the build-out of its new manufacturing plant.

Instead, it appears investors are worried about an update on the company's ALN-CC5, which caused three analysts to cut their price targets. It's all relative, of course, because all three analysts kept their buy or outperform ratings on the stock and the lowest of the new lower price targets is $107, substantially higher than where Alnylam trades today.

So what: Alnylam plans to present initial results from a phase 1/2 trial of ALN-CC5 in patients with paroxysmal nocturnal hemoglobinuria (PNH) at the European Hematology Association meeting next month, but management said the data point to developing the drug for PNH patients that are poor responders to Alexion's (ALXN) already-approved Soliris or as a backup medicine in between doses of Soliris. Not having to compete for PNH patients is obviously good news for Alexion, which saw its stock end Tuesday up 2.7%.

Being a second-line drug will cut into the potential patients that ALN-CC5 could be used to treat. Alnylam thinks it might be 20% to 30% of PNH patients whose symptoms aren't adequately controlled on Soliris. On the plus side, there will be less competition for those patients. Alnylam plans to start a phase 2 trial by the end of 2016 in patients that need additional treatment beyond Soliris.

There's also the possibility to test ALN-CC5 in other complement-mediated diseases. Alexion, for instance, has also gotten Soliris approved for a disease called atypical hemolytic uremic syndrome (aHUS). Management mentioned aHUS and another complement disease called myasthenia gravis as potential targets for clinical trials starting in early 2017.

Now what: While investors seem to be focused on lower potential sales of ALN-CC5 years from now, keep in mind that Alnylam has four drugs that are further along in the clinic. We should get an update on the open label extension trials for both patisiran and revusiran in July at the International Symposium on Amyloidosis. Alnylam plans to start a phase 3 trial for fitusiran in hemophilia patients later this year. And The Medicines Company plans to present initial phase 2 data on ALN-PCSsc later this year. Given that they're all closer to market, progress on all four drugs is more important than ALN-CC5.

Alnylam Pharmaceuticals is anticipating the trials being positive and the drugs getting on the market with its investment in a manufacturing plant. The company expects the facility to be operational in 2018, which works out well with phase 3 data for patisiran expected to read out next year. Making drugs in house could give Alnylam a little boost to any licensing deals, perhaps collecting a manufacturing fee in addition to a royalty.

While the ALN-CC5 news is disappointing, there were no guarantees that every RNAi drug from Alnylam was going to be a blockbuster, and investors should focus on the bigger picture.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alnylam Pharmaceuticals, Inc. Stock Quote
Alnylam Pharmaceuticals, Inc.
ALNY
$142.20 (-2.93%) $-4.29
Alexion Pharmaceuticals, Inc. Stock Quote
Alexion Pharmaceuticals, Inc.
ALXN
The Medicines Company Stock Quote
The Medicines Company
MDCO

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.